GlassScriptPhysician profile
Olga Schatz
NPI 1346560653
$2,002.19
in general payments reported to CMS, 2019-2025
14 companies · $64.93 in 2025
The $64.93 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $428 · 2020: $108 · 2021: $253 · 2022: $477 · 2023: $348 · 2024: $323 · 2025: $64.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $736.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $735.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $386.13 | 2021-2024 | Avycaz, Dalvance, Teflaro |
| Janssen Pharmaceuticals, INC | $253.57 | 2019-2023 | Xarelto |
| Pfizer INC. | $244.18 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $214.75 | 2019-2025 | Eliquis |
| Impulse Dynamics (USA) INC. | $172.72 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $171.43 | 2019-2023 | Farxiga |
| Medtronic Vascular, INC. | $157.46 | 2019 | |
| Glaxosmithkline, LLC. | $121.87 | 2024 | Nucala |
| Allergan, INC. | $114.83 | 2019-2020 | |
| Melinta Therapeutics, LLC | $65.65 | 2019 | |
| Paratek Pharmaceuticals, INC. | $41.87 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $22.60 | 2023 | Inpefa |
| Merck Sharp & Dohme LLC | $18.80 | 2019 | |
| Novartis Pharmaceuticals Corporation | $16.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olga Schatz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.